Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SON 1010

Next Previous
Drug Profile

SON 1010

Alternative Names: IL12-FHAB; SON-1010

Latest Information Update: 19 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sonnet Biotherapeutics
  • Developer Sonnet BioTherapeutics Holdings, Inc
  • Class Antineoplastics; Immunoglobulin fragments; Immunoglobulin Fv fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Ovarian cancer; Solid tumours

Most Recent Events

  • 03 Feb 2026 Sonnet BioTherapeutics terminates a phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) in Australia and USA (SC) because trial failed to meet efficacy endpoint despite lack of safety concern (NCT05756907)
  • 15 Oct 2025 Sonnet BioTherapeutics collaborates with Spanios for SON-1010 for Cancer
  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top